舒必利联合舍曲林治疗首发精神分裂症研究

A study of sulpiride combined with sertraline in the treatment of first episode schizophrenia

目的:评估舒必利联合舍曲林治疗首发精神分裂症的临床疗效及对患者生活质量的影响。方法:将首发精神分裂症患者66例随机分为联合治疗组和舒必利组。联合治疗组使用舒必利联合舍曲林治疗,舒必利组单用舒必利治疗。于治疗前及治疗8周末采用阳性与阴性症状量表(PANSS)评估疗效,采用健康状况调查问卷(SF-36)评估生活质量,以及治疗中出现的症状量表(TESS)评估不良反应。结果:治疗8周末,联合治疗组的PANSS总分、阴性症状、一般精神病理、反应缺乏、抑郁以及SF-36总分、生理机能、生理职能、生活活力、社会功能、情感职能5个领域均显著优于舒必利组,两组不良反应无差异。结论:舒必利联合舍曲林治疗能提高首发精神分裂症的临床疗效,改善生活质量。

Objective：To assess the clinical efficacy and the quality of life of sulpiride combined with sertraline in the treatment of first episode schizophrenia. Method： Sixty-six first episode schizophrenia were randomly assigned into combined group （snlpiride combined with sertraline） and snlpiride group （sulpiride only ）. Positive and negative syndrome scale （PANSS） was used for clinical efficacy evaluation, shortform-36 health survey （SF-36） for the quality of life,treatment emergent symptoms scale （TESS） for adverse effect before and after 8 treatment weeks. Results： After 8 treatment weeks, scores in total PANSS, negative symptom, general psychopathology symptom, reaction deficit, depression and scores in total SF-36, physical functioning, role-physical, vitality, social functioning, role-emotional in combined group were significantly better than that in sulpiride group. There was no significant difference in adverse effects between the two groups. Conclusion： Sulpifide combined with sertraline can significantly improve clinical efficacy and benefit the quality of life of first episode schizophrenia.